Analysis of endoplasmic reticulum stress in placentas of HIV-infected women treated with protease inhibitors

Reproductive Toxicology

Volumn 50, Issue , 2014, Pages 122-128

  Brüning, Ansgar ^a   Kimmich, Tanja ^a   Brem, German J ^a   Buchholtz, Marie L ^a   Mylonas, Ioannis ^a   Kost, Bernd ^a   Weizsäcker, Katharina ^b   Gingelmaier, Andrea ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adverse effect; Endoplasmic reticulum stress; Mother to child transmission; Placenta; Protease inhibitor; XBP1

Indexed keywords

ATAZANAVIR; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR DISOPROXIL; X BOX BINDING PROTEIN 1; ZIDOVUDINE; DNA BINDING PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; REGULATORY FACTOR X TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ADULT; ARTICLE; AUTOPHAGY; CESAREAN SECTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; ENDOPLASMIC RETICULUM STRESS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; PLACENTA; POLYMERASE CHAIN REACTION; PREGNANT WOMAN; RNA SPLICING; TROPHOBLAST; UNSPECIFIED SIDE EFFECT; CELL CULTURE; DRUG EFFECTS; GENETICS; HIV INFECTIONS; METABOLISM; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

ADULT; AUTOPHAGY; CELLS, CULTURED; DNA-BINDING PROTEINS; ENDOPLASMIC RETICULUM STRESS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRANSCRIPTION FACTORS;

EID: 84910146866     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2014.10.012     Document Type: Article

References (34)

1. Tran H., Robinson S., Mikhailenko I., Strickland D.K. Modulation of the LDL receptor and LRP levels by HIV protease inhibitors. J Lipid Res 2003, 44:1859-1869.
2. Zhou H., Pandak W.M., Lyall V., Natarajan R., Hylemon P.B. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 2005, 68:690-700.
3. Adler-Wailes D.C., Guiney E.L., Koo J., Yanovski J.A. Effects of ritonavir on adipocyte gene expression: evidence for a stress-related response. Obesity (Silver Spring) 2008, 16:2379-2387.
4. Wu X., Sun L., Zha W., Studer E., Gurley E., Chen L., et al. HIV protease inhibitors induce endoplasmic reticulum stress and disrupt barrier integrity in intestinal epithelial cells. Gastroenterology 2010, 138:197-209.
5. Brüning A. Analysis of nelfinavir-induced endoplasmic reticulum stress. Methods Enzymol 2011, 491:127-142.
6. Brüning A., Friese K., Burges A., Mylonas I. Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. Breast Cancer Res 2010, 12:R45.
7. Ozcan L., Tabas I. Role of endoplasmic reticulum stress in metabolic disease and other disorders. Annu Rev Med 2012, 63:317-328.
8. Gorman A.M., Healy S.J., Jäger R., Samali A. Stress management at the ER: regulators of ER stress-induced apoptosis. Pharmacol Ther 2012, 134:306-316.
9. Cebollero E., Reggiori F., Kraft C. Reticulophagy and ribophagy: regulated degradation of protein production factories. Int J Cell Biol 2012, 2012:182834.
10. Su J., Zhou L., Kong X., Yang X., Xiang X., Zhang Y., et al. Endoplasmic reticulum is at the crossroads of autophagy, inflammation, and apoptosis signaling pathways and participates in the pathogenesis of diabetes mellitus. J Diabetes Res 2013, 2013:193461.
11. Chou J.Y. Human placental cells transformed by tsA mutants of simian virus 40: a model system for the study of placental functions. Proc Natl Acad Sci USA 1978, 75:1409-1413.
12. Kohler P.O., Bridson W.E. Isolation of hormone-producing clonal lines of human choriocarcinoma. J Clin Endocrinol Metab 1971, 32:683-687.
13. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008, 3:1101-1108.
14. Gingelmaier A., Kurowski M., Kästner R., Eberle J., Mylonas I., Belohradsky B.H., et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 2006, 20:1737-1743.
15. Cressey T.R., Van Dyke R., Jourdain G., Puthanakit T., Roongpisuthipong A., Achalapong J., et al. IMPAACT P1032 Team. Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. Antimicrob Agents Chemother 2009, 53:2189-2191.
16. Conradie F., Zorrilla C., Josipovic D., Botes M., Osiyemi O., Vandeloise E., et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med 2011, 12(October (9)):570-579.
17. Biederbick A., Kern H.F., Elsässer H.P. Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. Eur J Cell Biol 1995, 66:3-14.
18. Gingelmaier A., Grubert T.A., Kost B.P., Setzer B., Lebrecht D., Mylonas I., et al. Mitochondrial toxicity in HIV type-1-exposed pregnancies in the era of highly active antiretroviral therapy. Antivir Ther 2009, 14:331-338.
19. Weinberg A., Forster-Harwood J., Davies J., McFarland E.J., Pappas J., Kinzie K., et al. Safety and tolerability of antiretrovirals during pregnancy. Infect Dis Obstet Gynecol 2011, 2011:867674.
20. Cotter A.M., Garcia A.G., Duthely M.L., Luke B., O'Sullivan M.J. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth. J Infect Dis 2006, 193:1195-2201.
21. Kourtis A.P., Schmid C.H., Jamieson D.J., Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007, 21:607-615.
22. Iwawaki T., Akai R., Yamanaka S., Kohno K. Function of IRE1 alpha in the placenta is essential for placental development and embryonic viability. Proc Natl Acad Sci USA 2009, 106:16657-16662.
23. Yoshida H. ER stress and diseases. FEBS J 2007, 274:630-658.
24. Wang S., Kaufman R.J. The impact of the unfolded protein response on human disease. J Cell Biol 2012, 197:857-867.
25. Yung H.W., Calabrese S., Hynx D., Hemmings B.A., Cetin I., Charnock-Jones D.S., et al. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am J Pathol 2008, 173:451-462.
26. Yung H.W., Hemberger M., Watson E.D., Senner C.E., Jones C.P., Kaufman R.J., et al. Endoplasmic reticulum stress disrupts placental morphogenesis: implications for human intrauterine growth restriction. J Pathol 2012, 10.1002/path.4068.
27. Simon A., Warszawski J., Kariyawasam D., Le Chenadec J., Benhammou V., Czernichow P., et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA 2011, 306:70-78.
28. Sibiude J., Warszawski J., Tubiana R., Dollfus C., Faye A., Rouzioux C., et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost. Clin Infect Dis 2012, 54:1348-1360.
29. Chen L., Jarujaron S., Wu X., Sun L., Zha W., Liang G., et al. HIV protease inhibitor lopinavir-induced TNF-alpha and IL-6 expression is coupled to the unfolded protein response and ERK signaling pathways in macrophages. Biochem Pharmacol 2009, 78:70-77.
30. Djedaini M., Peraldi P., Drici M.D., Darini C., Saint-Marc P., Dani C., et al. Lopinavir co-induces insulin resistance and ER stress in human adipocytes. Biochem Biophys Res Commun 2009, 386:96-100.
31. 2+ homeostasis and potentiate alcoholic stress and injury in mice and primary mouse and human hepatocytes. Hepatology 2012, 56:594-604.
32. Aboud M., Elgalib A., Kulasegaram R., Peters B. Insulin resistance and HIV infection: a review. Int J Clin Pract 2007, 61:463-472.
33. Mitanchez D., Burguet A., Simeoni U. Infants born to mothers with gestational diabetes mellitus: mild neonatal effects, a long-term threat to global health. J Pediatr 2014, 164:445-450.
34. Back S.H., Kaufman R.J. Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem 2012, 81:767-793.